Concepedia

Publication | Open Access

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

DOIFull Paper Access

2.6K

Citations

36

References

2003

Year

Paul G. Richardson, Bart Barlogie, James R. Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Gordan Srkalović, Melissa Alsina, Raymond Alexanian,
New England Journal of Medicine

Abstract

Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

References

YearCitations

Page 1